MLYS
Mineralys Therapeutics, Inc. Health Care Pharmaceutical Preparations Russell 3000
$18.18Close
$1.5BMarket cap
$18.18 – $47.3352-week range
Nov 4, 2026Next report · after the close
Highlights
Cautions
- Not in an uptrend 0 of 8 trend conditions
- Lagging the market RS 5 · weaker than 95% of stocks over 12 months
- Far from its high 62% below its 52-week high
- Results soon Nov 4, 2026, in 3 days
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
62%
1wk
down 11.5%
price change
1mo
down 27.7%
price change
12-month return
down 56%
market up 11% ·
its own down 66%
F-score
—
— Not assessed
Altman Z
—
Unknown
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
2.3×
price / book
Earnings yield
down 13.0%
EBIT / enterprise value
Cheaper than
—
of the market · not assessed
Revenue growth
—
year on year
EPS growth
—
latest quarter
Sales growth
—
latest quarter
ROE
down 37%
return on equity
Free cash margin
—
-$142.4M FCF
D/E
—
long-term debt / equity
Net debt / EBITDA
—
Interest cover
—EBIT / interest
Trade setup
ATR%
7.6%
$1.38 a day · 2×ATR $15.43
RS
5 / 99
vs the universe
Trend
0 / 8
trend template
Relative volume
3.0×
vs 50-day average
Up/down volume
0.76
50 sessions
Implied move
—
no option chain · report Nov 4, 2026
Trend template · 0 of 8
Screen verdict
Did not qualify for any screen.
Warning signs
- Shareholders diluted The share count rose 63.7% over the year, from 50m to 82m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
Last reported
Aug 11, 2026
Last shock
Oct 30, 2026-14% in one session2.8× volumeon an SEC filing0% since
Financials
- Cash
- Long-term debt
| FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|
| Operating income | -$31.5M | -$84.7M | -$192.4M | -$170.6M |
| Net income | -$29.8M | -$71.9M | -$177.8M | -$154.7M |
| Earnings per share | -$5.77 | -$1.99 | -$3.66 | -$2.29 |
| Free cash flow | -$29.2M | -$81.2M | -$166.4M | -$142.4M |
| Cash | $87.7M | $49.3M | $114.1M | $172.9M |
| Shareholders' equity | -$52.3M | $241.2M | $191.3M | $646.7M |
| Shares outstanding | 6.42m | 41.13m | 49.82m | 81.54m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 11, 2026 | Quarterly ↗ | Jun 30, 2026 | 42d |
| May 6, 2026 | Quarterly ↗ | Mar 31, 2026 | 36d |
| Mar 12, 2026 | Annual ↗ | Dec 31, 2025 | 71d |
| Nov 10, 2025 | Quarterly ↗ | Sep 30, 2025 | 41d |
| Aug 12, 2025 | Quarterly ↗ | Jun 30, 2025 | 43d |
| May 12, 2025 | Quarterly ↗ | Mar 31, 2025 | 42d |
| Feb 12, 2025 | Annual ↗ | Dec 31, 2024 | 43d |
| Nov 12, 2024 | Quarterly ↗ | Sep 30, 2024 | 43d |
| Aug 13, 2024 | Quarterly ↗ | Jun 30, 2024 | 44d |
| May 9, 2024 | Quarterly ↗ | Mar 31, 2024 | 39d |
| Mar 21, 2024 | Annual ↗ | Dec 31, 2023 | 81d |
| Nov 7, 2023 | Quarterly ↗ | Sep 30, 2023 | 38d |
Current reports
| Filed | Disclosed |
|---|---|
| Oct 29, 2026 | Material agreement · Agreement ended ↗ |
| Oct 19, 2026 | Director or officer change ↗ |
| Aug 11, 2026 | Results · Director or officer change ↗ |
| Jun 3, 2026 | Other events ↗ |
| Jun 3, 2026 | Material agreement · New obligation ↗ |
| May 22, 2026 | Shareholder vote ↗ |
| May 6, 2026 | Results ↗ |
| Mar 12, 2026 | Results ↗ |
| Mar 9, 2026 | Regulation FD · Other events ↗ |
| Jan 6, 2026 | Regulation FD · Other events ↗ |
| Nov 10, 2025 | Results ↗ |
| Sep 3, 2025 | Other events ↗ |